Liquid Pharmaceutical Formulations of PTH Conjugates
AssigneeAscendis Pharma Bone Diseases A/S
InventorsAnja R.H. SKANDS, Felix CLEEMANN, Michael Duelund SØRENSEN, Julia BARON, Eric HOFFMANN, Kennett SPROGØE
Life of this patent
Estimating the term…
Abstract
A liquid pharmaceutical formulation, wherein the pharmaceutical formulation comprises a PTH conjugate, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and wherein the PTH conjugate comprises a PTH moiety that is covalently and reversibly conjugated to a water-soluble carrier moiety.
Claims42
A liquid pharmaceutical formulation, wherein the pharmaceutical formulation comprises a PTH conjugate, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and wherein the PTH conjugate comprises a PTH moiety that is covalently and reversibly conjugated to a water-soluble carrier.
The liquid pharmaceutical formulation of claim19, wherein —Z comprises a moiety:
39-42. (canceled)
The method of claim 39, wherein the disease is selected from the group consisting of hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, osteomalacia and osteoporosis in patients with hypophosphatasia, steroid-induced osteoporosis, male osteoporosis, arthritis, osteoarthritis, osteogenesis imperfecta, fibrous dysplasia, rheumatoid arthritis, Paget's disease, humoral hypercalcemia associated with malignancy, osteopenia, periodontal disease, bone fracture, alopecia, chemotherapy-induced alopecia and thrombocytopenia, chronic periodontitis, osteonecrosis of jaw and poorly healing fractures due to ALPL gene mutations.
Dependencies are inferred from the claim text.